Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as Ozempic or Wegovy, have revolutionized type 2 diabetes and weight-loss management, but they have also led to some unfortunate outcomes. A recent study in JAMA Psychiatry has raised concerns that GLP-1 medications may be misused by people with eating disorders. These are serious mental health conditions in which thoughts about food, body weight and body shape become overwhelming, leading to harmful eating behaviors and an intense drive to control food intake. Although concerns about weight or appearance are common, eating disorders go far beyond these everyday worries.
Original Source Link


